Blockchain Registration Transaction Record

Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Boost Market Appeal

Calidi Biotherapeutics (CLDI) announces a 1-for-12 reverse stock split effective August 2025, aiming to optimize market dynamics and investor appeal in its quest to revolutionize cancer treatment.

This news is significant for investors and the biotech industry as it highlights Calidi Biotherapeutics' strategic steps to strengthen its market position and investor base through a reverse stock split. The company's innovative approach to cancer treatment, utilizing stem cell-based platforms for delivering oncolytic viruses, represents a potential breakthrough in immuno-oncology. For stakeholders, this move could signal confidence in the company's growth trajectory and its commitment to advancing cancer therapies. Additionally, the role of BioMedWire in disseminating such news underscores the importance of specialized communication platforms in the biotech sector, ensuring that critical developments reach the right audiences efficiently.